SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · United Therapeutics CEO Martine Rothblatt and other insiders engaged in…

UNITED THERAPEUTICS Corp · CLUSTER filed Mar 16, 2026 at 16:31 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Mar 16, 2026 at 16:31 ET

United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market sales over the past week, generating $2.8 million in total proceeds from stock sales. The activity is primarily tied to option exercises and tax-related sales, with the CEO accounting for the majority of transactions.

  • CEO Martine Rothblatt exercised options for 95,000 shares across multiple days (10 tranches of 9,500 shares), with 5 tranches at $146.03 (total value $6.94M) and 5 at $0 (non-cash).
  • Rothblatt sold 852 shares in open-market transactions totaling $447,085.17 at prices between $520.34 and $531.21.
  • EVP Paul Mahon exercised options for 16,600 shares at $146.03 (value $2.42M) and sold 753 shares for $397,183.86.
  • Director Jan Malcolm sold 45 shares for $24,007.95.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access